

Multi-Inflammatory Syndrome in Children (MIS-C) West Virginia

Maria del Rosario, MD, MPH
Director of Surveillance

Division of Infectious Disease Epidemiology (DIDE)
Office of Epidemiology and Prevention Services
WV Immunization Summit

June 9, 2023



Objectives

- Inform on the process of MIS-C surveillance in West Virginia.
- Describe MIS-C morbidity in West Virginia.

2020 Case Definition:

- Person <21 years old presenting with fever, lab. evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement; AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.

2023 Case Definition (revised):

- Duration of fever not required
- CRP \geq 3mg/dl to indicate systemic inflammation
- Organ system involvement criteria adjusted to include shock. Removed respiratory, neurologic, renal criteria
- Timing of positive SARS-CoV-2 lab test relative to MIS-C illness

MIS-C is a severe hyperinflammatory condition occurring two to six weeks after infection with SARS-CoV-2.



MIS-C detection in West Virginia

- Surveillance
 - Syndromic surveillance
 - Active surveillance at three West Virginia tertiary/pediatric hospitals using ICD-10 codes
- MIS-C nurse investigates, information is reported to the Centers for Disease Control and Prevention (CDC)
- Voluntary reporting to CDC

MIS-C Surveillance

MIS-C Cases (February 2020 to March 2023)	United States	West Virginia
Total MIS-C cases	9,445	42
Death	78	0

Reported MIS-C Case Ranges by Jurisdiction, on or before March 31, 2023



MIS-C Case Counts in West Virginia, n=42

YEAR OF REPORT	2021	2022	2023
Total number investigated	340	105	17
Total number of MIS-C cases	23	18	1
AGE GROUP (BY YEARS)			
<1	0	1	0
1 to 4	3	3	0
5 to 11	12	11	1
12 to 15	5	2	0
16-20	3	1	0

MIS-C Case Demographics

Demographics	2021	2022	2023
GENDER			
Male	18	9	1
Female	5	9	0
RACE and ETHNICITY			
Asian	0	0	0
Black	0	1	0
Hispanic	0	0	0
White	22	16	1
Other/Multiple	1	0	0
Missing	0	1	0

Clinical Features and Underlying Condition

Health Status	2021	2022	2023
CLINICAL FEATURES			
Fever \leq 2 days	2	2	0
Fever \geq 3 days	21	16	1
Missing/Unknown	0	0	0
UNDERLYING MEDICAL CONDITION (n=10)			
Obesity*	4	2	0
Chronic Lung Disease (including Asthma)	1	3	0
Missing/Unknown	0	0	0

*Obesity was determined using CDC's [BMI table](#)

Organ System Involvement

ORGAN SYSTEM	2021	2022	2023
Hematologic	21	15	1
Gastrointestinal	17	13	1
Dermatologic	15	13	1
Cardiac	13	9	0
Respiratory	7	6	1
Neurologic	2	3	0
Renal	3	2	0
Missing or Unknown	0	0	0

Cases may have more than 1 organ system involvement.

Treatment

TREATMENT	2021	2022	2023
IV Immunoglobulins	18	14	1
Systemic corticosteroids	18	13	1
Other immunomodulatory treatment (anakinra)	3	2	0
No immunomodulatory treatment	20	16	0
Extracorporeal Membrane Oxygenation (ECMO)	0	1	0

Cases may have received more than 1 type of treatment.

Clinical Outcome

OUTCOMES	2021	2022	2023
Total number of MIS-C cases admitted to hospital	23	18	1
Total days in hospital, median*	6	2	3
Total number of MIS-C cases in ICU	9	5	0
Death	0	0	0
Missing or Unknown	0	0	0

All MIS-C cases have improved or are improving.

*Estimate median by counting the number of MIS-C cases and arrange the cases in increasing order of number of hospital days. If the number of cases is uneven, add 1 and divide the results by 2 to get the rank of the data point whose value is the median.

Summary

- Main risk factor: SARS-CoV-2 infection
- Most children with MIS-C do not have any reported underlying medical conditions. For those with underlying medical condition, obesity is the most common.
- Protect a child from MIS-C:
 - ✓ [Stay Up to Date with COVID-19 Vaccines Including Boosters](#)
 - ✓ [How to Protect Yourself and Others](#)
- MIS-C Resources for Healthcare Providers:
<https://www.cdc.gov/mis/mis-c/hcp/provider-resources/index.html>

Acknowledgement

1. U.S. Department of Health and Human Services and CDC*
2. Lesley Roush, RN – MIS-C Abstractor
3. Three West Virginia hospitals:
 - West Virginia University Hospital System
 - Cabell-Huntington Hospital
 - Charleston Area Medical Centers (CAMC)
4. West Virginia Department of Health and Human Resources, Office of Epidemiology and Prevention Services and Office of Management Information Systems

*Supported by the ELC ENHANCING DETECTION THROUGH CORONAVIRUS RESPONSE AND RELIEF funding of the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$103,153,083 with 100 percentage funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. government.

Contact

Lesley Roush, RN
MIS-C Nurse Reviewer/Abstractor
West Virginia Department of Health and Human Resources
Bureau for Public Health
Office of Epidemiology and Prevention Services
Division of Infectious Disease Epidemiology
350 Capitol Street, Room 125
Charleston, West Virginia 25301
Phone: 304-558-5358, ext. 2
Fax: 304-558-8736
Email: lesley.a.roush@wv.gov
Website: www.oeps.wv.gov